Personalized Treatment of Rare Cancers Based on Comprehensive Diagnostics: Case Reports of Two Neuroendocrine Breast Cancers | Chapter 11 | Current Innovations in Medicine and Medical Science Vol. 4

 The current case study highlights the diagnostic and treatment difficulties that two patients with NEBC experienced throughout their epicrisis in the aforementioned circumstances. One percent of all neuroendocrine tumours and 0.1% of all breast carcinomas are caused by the rare disease known as neuroendocrine breast cancer (NEBC) [6]. Here, we offer two case reports of NEBC cohorts with large cell and small cell diagnoses in the absence of prospective trial data. When the first treatments failed, thorough tumour profiling was used to produce tailored treatment plans for both patients. Targetable changes of the PI3K/AKT/mTOR pathway, including a PIK3CA mutation and a STK11 mutation that inhibits the mTOR complex, were discovered in both individuals. The two patients' epicrisis serves as an example of how to manage rare and challenging cancers and how modern diagnostic techniques support medical management. The earlier we consider adopting customised medicines based on thorough tumour features, the sooner we can determine whether this strategy will be beneficial. Trials focused on a variety of uncommon cancer types and thorough profiling may contain the secret to an effective cure.

Author(s) Details:

Dörthe Schaffrin-Nabe,
Praxis für Hämatologie und Onkologie, Bochum, Germany.

Anke Josten-Nabe,
Praxis für Hämatologie und Onkologie, Bochum, Germany.

Stefan Schuster,
Datar Cancer Genetics Europe GmbH, Eckersdorf, Germany.

Andrea Tannapfel,
Institute of Pathology, Ruhr-University Bochum, Bochum, Germany.

Rudolf Voigtmann,
Praxis für Hämatologie und Onkologie, Bochum, Germany.

Please see the link here: https://stm.bookpi.org/CIMMS-V4/article/view/8401